
Tricida TCDA
Quarterly report 2022-Q3
added 11-14-2022
Tricida Current Ratio 2011-2026 | TCDA
Annual Current Ratio Tricida
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 9.17 | 7.87 | 16.5 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 16.5 | 1 | 8.63 |
Quarterly Current Ratio Tricida
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 0.41 | 0.51 | 0.61 | 1 | 1.01 | 1.22 | 1.35 | 1.45 | 1.45 | 1.45 | 1.45 | 3.44 | 3.44 | 3.44 | 3.44 | 4.65 | 4.65 | 4.65 | 4.65 | 6.11 | 6.11 | 6.11 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.11 | 0.41 | 2.85 |
Current Ratio of other stocks in the Drug manufacturers industry
| Issuer | Current Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals
AERI
|
0.961 | - | - | $ 754 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
1.78 | - | 7.5 % | $ 6.35 M | ||
|
Catalent
CTLT
|
1.59 | - | - | $ 11.5 B | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
0.944 | - | 0.86 % | $ 117 M | ||
|
Canopy Growth Corporation
CGC
|
2.13 | $ 1.07 | -0.47 % | $ 115 M | ||
|
DURECT Corporation
DRRX
|
1.95 | - | - | $ 50.1 M | ||
|
Endo International plc
ENDP
|
1.77 | - | - | $ 28.9 M | ||
|
Agile Therapeutics
AGRX
|
0.386 | - | 10.11 % | $ 58.2 M | ||
|
Evoke Pharma
EVOK
|
0.733 | - | - | $ 36.6 M | ||
|
Alimera Sciences
ALIM
|
1.43 | - | - | $ 142 M | ||
|
Harrow Health
HROW
|
1.15 | $ 38.95 | -27.32 % | $ 1.43 B | ||
|
Cronos Group
CRON
|
6.63 | $ 2.62 | -0.57 % | $ 1.36 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
1.82 | - | - | $ 2.06 B | ||
|
Jupiter Wellness
JUPW
|
0.772 | - | - | $ 33.6 M | ||
|
China Pharma Holdings
CPHI
|
2.09 | $ 0.55 | -0.97 % | $ 9.61 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
1.43 | $ 4.5 | -7.02 % | $ 63.3 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
9.82 | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
1.85 | - | 2.45 % | $ 38.1 M | ||
|
Neoleukin Therapeutics
NLTX
|
6.09 | - | - | $ 193 M | ||
|
Aurora Cannabis
ACB
|
3.49 | $ 3.52 | -5.26 % | $ 86.3 M | ||
|
Athenex
ATNX
|
0.894 | - | -23.39 % | $ 1.76 M | ||
|
Organogenesis Holdings
ORGO
|
4.42 | $ 2.86 | -4.67 % | $ 377 M | ||
|
Emergent BioSolutions
EBS
|
1.55 | $ 8.87 | -1.33 % | $ 454 M | ||
|
ProPhase Labs
PRPH
|
3.65 | - | - | $ 5.07 M | ||
|
Assertio Holdings
ASRT
|
1.93 | $ 11.92 | 1.24 % | $ 847 M | ||
|
Radius Health
RDUS
|
0.418 | - | - | $ 1.42 B | ||
|
Rockwell Medical
RMTI
|
1.69 | $ 0.9 | 0.37 % | $ 21 M | ||
|
Evolus
EOLS
|
0.907 | $ 4.21 | -1.86 % | $ 261 M | ||
|
Bausch Health Companies
BHC
|
0.997 | $ 5.77 | -3.11 % | $ 2.11 B | ||
|
Lannett Company
LCI
|
0.659 | - | 1.15 % | $ 7.11 M | ||
|
Eagle Pharmaceuticals
EGRX
|
2.35 | - | -39.89 % | $ 27.7 M | ||
|
OrganiGram Holdings
OGI
|
4 | $ 1.38 | -3.17 % | $ 402 M | ||
|
Perrigo Company plc
PRGO
|
1.52 | $ 11.38 | -7.97 % | $ 1.58 B | ||
|
Sundial Growers
SNDL
|
6.25 | $ 1.53 | 0.33 % | $ 3.37 M | ||
|
Pacira BioSciences
PCRX
|
2 | $ 22.06 | 3.67 % | $ 1.02 B | ||
|
PetIQ
PETQ
|
2.4 | - | 1.64 % | $ 400 M | ||
|
OptiNose
OPTN
|
0.554 | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
3.07 | - | -27.8 % | $ 2.56 M | ||
|
Recro Pharma
REPH
|
1.62 | - | -4.76 % | $ 65.3 M | ||
|
Relmada Therapeutics
RLMD
|
8 | $ 4.67 | -3.51 % | $ 141 M | ||
|
SCYNEXIS
SCYX
|
2.32 | $ 0.73 | -2.19 % | $ 34.9 M | ||
|
Solid Biosciences
SLDB
|
3.67 | $ 5.99 | -3.47 % | $ 244 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
1.48 | $ 2.76 | -2.66 % | $ 3.43 M | ||
|
TherapeuticsMD
TXMD
|
3.09 | $ 2.26 | 1.0 % | $ 23.6 M | ||
|
Tilray
TLRY
|
4.41 | $ 7.37 | -2.97 % | $ 4.55 B | ||
|
Veru
VERU
|
2.15 | $ 2.54 | -3.05 % | $ 343 M | ||
|
Viatris
VTRS
|
1.73 | $ 15.09 | -3.89 % | $ 18.1 B | ||
|
Zynerba Pharmaceuticals
ZYNE
|
5.98 | - | - | $ 55.5 M | ||
|
cbdMD
YCBD
|
1.23 | $ 0.79 | -2.48 % | $ 3.41 M |